Medomeksi solution for injection 50mg / ml, 5 ml No. 5

• acute cerebrovascular accidents of ischemic type (as part of complex therapy)

• encephalopathy

• vegetative-vascular dystonia

• anxiety in neurotic and neurosis-like states

• mild cognitive impairment of vascular origin

• age-related decline in cognitive functions in the elderly (memory, orientation, concentration disorders)

• asthenic conditions, under the influence of extreme (stress) factors

• withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders

• acute intoxication with antipsychotic drugs

Assign intramuscularly or intravenously (jet or drip). Doses are selected individually. When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The drug is injected in a jet slowly over 5-7 minutes, drip - at a rate of 40-60 drops per minute. The maximum daily dose does not exceed 800 mg.
In case of acute disorders of cerebral circulation, it is used in complex therapy in the first 2-4 days by intravenous drip of 200-300 mg once a day, then intramuscularly at 100 mg 3 times a day. The duration of treatment is 10-14 days. In case of discirculatory encephalopathy in the decompensation phase, the drug should be administered intravenously by jet or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is injected intramuscularly at 100 mg 2-3 times a day for the next 2 weeks. For the course prevention of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days. For mild cognitive impairments, age-related decline in cognitive functions and for anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg for 14-30 days.
With vegetative-vascular dystonia, asthenic conditions, neurotic and neurosis-like states - intramuscularly at 50-400 mg / day for 14 days. In case of alcohol withdrawal syndrome, the drug is administered in a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.

1 ml of solution contains:
Active substance:
ethylmethylhydroxypyridine succinate - 50 mg
Excipients:
sodium disulfite (sodium metabisulfite) - 1 mg water for injection up to 1 ml.

Acute hepatic and / or renal failure, increased individual sensitivity to the drug. Childhood, pregnancy, breastfeeding - due to lack of data.

Carefully

History of allergic diseases (for parenteral administration).

Trade name of the drug : Medomeksi

International non-proprietary or group name : Ethylmethylhydroxypyridine succinate

Chemical rational name : 3-Hydroxy-6-methyl-2-ethylpyridine succinate.

Dosage form : solution for intravenous and intramuscular administration.

Ingredients :

1 ml of solution contains:
Active substance:
ethylmethylhydroxypyridine succinate - 50 mg
Excipients:
sodium disulfite (sodium metabisulfite) - 1 mg water for injection up to 1 ml.

Description : Colorless or slightly yellowish transparent liquid.

Pharmacotherapeutic group : Antioxidant agent

ATX code : N07XX

Pharmacological properties

Pharmacodynamics
The drug Medomeksi belongs to heteroaromatic antioxidants. The drug improves the metabolism of brain tissues and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes membrane structures of erythrocytes and platelets.
The mechanism of action is due to its antioxidant and membrane-protective action. The drug inhibits lipid peroxidation, increases the activity of the enzyme superoxide dismutase, increases the lipid-protein ratio in the cell membrane, stabilizes blood cell membranes, reduces blood viscosity, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biomembranes and transport of neuromembranes. Increases the content of dopamine in the brain.It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
Has a wide range of pharmacological activity: increases the body's resistance to stress, exhibits anxiolytic effect, not accompanied by drowsiness and muscle relaxant effect; possesses nootropic properties helps to improve memory, facilitates learning processes, improves concentration and mental activity; has an anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol.

Pharmacokinetics
The value of the maximum concentration (Cmax) of the drug in the blood plasma after intramuscular administration is 0.3-0.58 hours. Cmax when administered intramuscularly at a dose of 400-500 mg is 2.5-4 ?g / ml. It is quickly distributed in organs and tissues. The half-life (T1 / 2) and the average retention time of the drug in the body with intramuscular administration is 0.7-1.3 hours. It is metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate is formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, is formed in large quantities and is found in urine for 1-2 days after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates.The drug is excreted in the urine mainly in the form of metabolites (50% in 12 hours) and in a small amount - unchanged (0.3% in 12 hours). The most intensively excreted during the first 4 hours after taking the drug. The rates of excretion in the urine of unchanged drug and metabolites have significant individual variability.

Indications for use

• acute cerebrovascular accidents of ischemic type (as part of complex therapy)

• encephalopathy

• vegetative-vascular dystonia

• anxiety in neurotic and neurosis-like states

• mild cognitive impairment of vascular origin

• age-related decline in cognitive functions in the elderly (memory, orientation, concentration disorders)

• asthenic conditions, under the influence of extreme (stress) factors

• withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders

• acute intoxication with antipsychotic drugs

Contraindications

Acute hepatic and / or renal failure, increased individual sensitivity to the drug. Childhood, pregnancy, breastfeeding - due to lack of data.

Carefully

History of allergic diseases (for parenteral administration).

Method of administration and dosage

Assign intramuscularly or intravenously (jet or drip). Doses are selected individually. When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The drug is injected in a jet slowly over 5-7 minutes, drip - at a rate of 40-60 drops per minute. The maximum daily dose does not exceed 800 mg.
In case of acute disorders of cerebral circulation, it is used in complex therapy in the first 2-4 days by intravenous drip of 200-300 mg once a day, then intramuscularly at 100 mg 3 times a day. The duration of treatment is 10-14 days. In case of discirculatory encephalopathy in the decompensation phase, the drug should be administered intravenously by jet or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is injected intramuscularly at 100 mg 2-3 times a day for the next 2 weeks. For the course prevention of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days. For mild cognitive impairments, age-related decline in cognitive functions and for anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg for 14-30 days.
With vegetative-vascular dystonia, asthenic conditions, neurotic and neurosis-like states - intramuscularly at 50-400 mg / day for 14 days. In case of alcohol withdrawal syndrome, the drug is administered in a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.

Side effect

With parenteral administration (especially intravenous jet): dryness of the oral mucosa, 'metallic' taste in the mouth, a feeling of 'spreading warmth' throughout the body, unpleasant odor, sore throat and chest discomfort, feeling of lack of air (usually are associated with an excessively high rate of administration and are short-lived); with prolonged use - nausea, flatulence; sleep disturbance (drowsiness or trouble falling asleep).

Overdose

Symptoms: Sleep disturbance (insomnia, in some cases drowsiness). Treatment, as a rule, is not required - the symptoms disappear on their own within 24 hours. In severe cases of insomnia, it is recommended to take sleeping pills. Symptoms: With intravenous administration - a slight and short-term (up to 1.5-2 hours) increase in blood pressure. Treatment: With an excessive increase in blood pressure - antihypertensive drugs under the control of blood pressure.

Interaction with other drugs

Medomeksi is compatible with psychotropic drugs; enhances the effect of benzodiazepine anxiolytics, antiparkinsonian drugs and carbamazepine; enhances the effect of nitrates.

special instructions

During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Release form

Solution for intravenous and intramuscular administration of 50 mg / ml.
2 ml or 5 ml in neutral glass ampoules.
5 ampoules in a blister strip made of polyvinyl chloride film and aluminum foil, printed varnished or flexible packaging based on aluminum foil, or without foil.
1 or 2 blister packs (with or without foil) together with instructions for use of the drug, a knife or ampoule scarifier in a cardboard box.
20, 50 or 100 blisters with foil, together with 10, 25 or 50 instructions for use of the drug, respectively, with knives or ampoule scarifiers in a cardboard box or in a corrugated cardboard box (for hospital).
When packing ampoules with rings or break points, ampoule knives or scarifiers are not inserted.

Storage conditions

List B. In the dark place at a temperature not exceeding 25 ? C. Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date printed on the package.

Conditions of dispensing from pharmacies

On prescription.